<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746641</url>
  </required_header>
  <id_info>
    <org_study_id>Acta No. 197</org_study_id>
    <nct_id>NCT01746641</nct_id>
  </id_info>
  <brief_title>Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures</brief_title>
  <official_title>Remifentanil Versus Propofol With Target Controlled Infusion Effect Site for the Sedation of Patients During Gastrointestinal Endoscopic Procedures: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci칩n Universitaria de Ciencias de la Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital de San Jose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundaci칩n Universitaria de Ciencias de la Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare remifentanil and propofol for sedation of patients
      during endoscopic gastrointestinal procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The administration of sedation with target controlled infusion (TCI) systems could offer a
      safe alternative for the management of discomfort of patients undergoing endoscopic
      gastrointestinal procedures. However, what medication from those available for TCI would be
      the most appropriate is not known.

      Sixty-nine patients requiring a gastrointestinal endoscopic procedure were randomly assigned
      to receive a TCI effect site (e) of remifentanil (n=30) or propofol (n=39). The primary
      outcome was patient satisfaction. Secondary outcomes included gastroenterologist
      satisfaction, the proportion of adverse events between the two groups were compared
      (occurrence of cardiac arrhythmias, mild respiratory depression, major respiratory
      depression, bradycardia, hypotension, pain, nausea or vomiting, and lack of amnesia), and the
      level of consciousness.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Occurrence of severe respiratory depression in the remifentanil group.
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>At the end of the procedure, expected average of 30 minutes</time_frame>
    <description>Measured with a analog scale from 1 to 4:
Excellent.
Good.
Regular.
No.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastroenterologist satisfaction</measure>
    <time_frame>At the end of the procedure, expected average of 30 minutes</time_frame>
    <description>Measured with a analog scale from 1 to 4:
Excellent.
Good.
Regular.
No.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At the end of the procedure, expected average of 30 minutes</time_frame>
    <description>Occurrence of cardiac arrythmias, mild respiratory depression, severe respiratory depression, bradycardia, hypotension, pain, nausea or vomiting, absence of amnesia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Level of consciousness</measure>
    <time_frame>Every minute until the end of the procedure, expected average of 30 minutes</time_frame>
    <description>Ramsay scale.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.
Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.
Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <arm_group_label>Remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient undergoing elective higher, lower or mixed gastrointestinal endoscopy at
             Hospital de San Jose, Bogota, between January and December 2010.

          -  Be between 18 and 70 years old.

          -  American Society of Anesthesiology Physical Status classification between 1 and 3.

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Patients with difficult airway indicators.

          -  Pregnant women.

          -  Patients with chronic pain.

          -  Chronic opioid or benzodiazepine users (&gt;3 months).

          -  Allergy history to remifentanil or propofol or eggs.

          -  Psychoactive drug users.

          -  Smokers (&gt; 5 cigarettes per day in the previous 3 months).

          -  Body mass index &gt; 30.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis A Mu침oz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundacion Universitaria de Ciencias de la Salud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis E Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Universitaria de Ciencias de la Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundaci칩n Universitaria de Ciencias de la Salud</name>
      <address>
        <city>Bogota</city>
        <zip>11001000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>December 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>December 8, 2012</last_update_submitted>
  <last_update_submitted_qc>December 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Propofol</keyword>
  <keyword>Sedation</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Gastroenterology</keyword>
  <keyword>Target controlled infusion effect site</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

